Concurrent validity of provisional remission criteria for gout: a dual-energy CT study
暂无分享,去创建一个
[1] N. Dalbeth,et al. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual‐Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial , 2019, Arthritis & rheumatology.
[2] F. Becce,et al. Clinical Utility of Multi‐Energy Spectral Photon‐Counting Computed Tomography in Crystal Arthritis , 2019, Arthritis & rheumatology.
[3] L. Duley,et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial , 2018, The Lancet.
[4] W. Lems,et al. Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis , 2018, BMC Rheumatology.
[5] Hyon K. Choi,et al. Effects of Febuxostat in Early Gout , 2017, Arthritis & rheumatology.
[6] S. Nicolaou,et al. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol , 2017, Annals of the rheumatic diseases.
[7] A. Gerards,et al. No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission , 2017, Rheumatology.
[8] J. Budzik,et al. Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study , 2017, Arthritis Research & Therapy.
[9] C. Viroli,et al. Development and First Validation of a Disease Activity Score for Gout , 2016, Arthritis care & research.
[10] A. Ogdie,et al. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises , 2016, Arthritis care & research.
[11] F. Perez-Ruiz,et al. Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout , 2015, Arthritis care & research.
[12] M. Lell,et al. Tophus resolution with pegloticase: a prospective dual-energy CT study , 2015, RMD Open.
[13] S. Nicolaou,et al. Artifacts in dual-energy CT gout protocol: a review of 50 suspected cases with an artifact identification guide. , 2014, AJR. American journal of roentgenology.
[14] C. Díaz-Torné,et al. Concerns of Patients With Gout Are Incompletely Captured by OMERACT-Endorsed Domains of Measurement for Chronic Gout Studies , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[15] B. Krauss,et al. Gout tophus detection-a comparison of dual-energy CT (DECT) and histology. , 2014, Seminars in arthritis and rheumatism.
[16] W. Taylor,et al. Do Patient Preferences for Core Outcome Domains for Chronic Gout Studies Support the Validity of Composite Response Criteria? , 2013, Arthritis care & research.
[17] V. Bykerk,et al. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. , 2012, Rheumatology.
[18] S. Nicolaou,et al. Dual energy CT in gout: a prospective validation study , 2012, Annals of the rheumatic diseases.
[19] J. Singh,et al. Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10 , 2011, The Journal of Rheumatology.
[20] N. Dalbeth,et al. The Experience and Impact of Living With Gout: A Study of Men With Chronic Gout Using a Qualitative Grounded Theory Approach , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[21] J. Singh,et al. Outcome Domains for Studies of Acute and Chronic Gout , 2009, The Journal of Rheumatology.
[22] H. Genberg,et al. A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation , 2009, Transplantation.
[23] S. Nicolaou,et al. Dual energy computed tomography in tophaceous gout , 2008, Annals of the rheumatic diseases.
[24] M. Netea,et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1β by mononuclear cells through a caspase 1-mediated process , 2008, Annals of the rheumatic diseases.
[25] E. Pascual,et al. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout , 2007, Annals of the rheumatic diseases.
[26] F. Martinon,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.
[27] F. Perez-Ruiz,et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.
[28] W. Downie,et al. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. , 1987, British journal of clinical pharmacology.
[29] D. Mccarty,et al. Preliminary criteria for the classification of the acute arthritis of primary gout. , 1977, Arthritis and rheumatism.
[30] D. Mccarty,et al. Identification of urate crystals in gouty synovial fluid. , 1961, Annals of internal medicine.
[31] P. Hench. DIAGNOSIS AND TREATMENT OF GOUT AND GOUTY ARTHRITIS , 1941 .
[32] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..